Literature DB >> 19101096

Preoperative [18F]fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes.

Chun-Ta Liao1, Joseph Tung-Chieh Chang, Hung-Ming Wang, Shu-Hang Ng, Chuen Hsueh, Li-Yu Lee, Chih-Hung Lin, I-How Chen, Shiang-Fu Huang, Ann-Joy Cheng, Tzu-Chen Yen.   

Abstract

PURPOSE: Survival in oral cavity squamous cell carcinoma (OSCC) depends heavily on locoregional control. In this prospective study, we sought to investigate whether preoperative maximum standardized uptake value of the neck lymph nodes (SUVnodal-max) may predict prognosis in OSCC patients. METHODS AND MATERIALS: A total of 120 OSCC patients with pathologically positive lymph nodes were investigated. All subjects underwent a [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) scan within 2 weeks before radical surgery and neck dissection. All patients were followed up for at least 24 months after surgery or until death. Postoperative adjuvant therapy was performed in the presence of pathologic risk factors. Optimal cutoff values of SUVnodal-max were chosen based on 5-year disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). Independent prognosticators were identified by Cox regression analysis.
RESULTS: The median follow-up for surviving patients was 41 months. The optimal cutoff value for SUVnodal-max was 5.7. Multivariate analyses identified the following independent predictors of poor outcome: SUVnodal-max >or=5.7 for the 5-year neck cancer control rate, distant metastatic rate, DFS, DSS, and extracapsular spread (ECS) for the 5-year DSS and OS. Among ECS patients, the presence of a SUVnodal-max >or=5.7 identified patients with the worst prognosis.
CONCLUSION: A SUVnodal-max of 5.7, either alone or in combination with ECS, is an independent prognosticator for 5-year neck cancer control and survival rates in OSCC patients with pathologically positive lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101096     DOI: 10.1016/j.ijrobp.2008.09.045

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-14       Impact factor: 9.236

Review 2.  Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours.

Authors:  Giovanni Lucignani; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05       Impact factor: 9.236

3.  Computed tomography detection of extracapsular spread of squamous cell carcinoma of the head and neck in metastatic cervical lymph nodes.

Authors:  Joshua A Carlton; Adam W Maxwell; Lyndsey B Bauer; Sara M McElroy; Lester J Layfield; Humera Ahsan; Ajay Agarwal
Journal:  Neuroradiol J       Date:  2017-03-08

4.  Comparison of PET/CT with conventional imaging modalities (USG, CECT) in evaluation of N0 neck in head and neck squamous cell carcinoma.

Authors:  Ashutosh Chauhan; Pranjal Kulshrestha; Sanjay Kapoor; Harkirat Singh; M J Jacob; Maneel Patel; Manomoy Ganguly
Journal:  Med J Armed Forces India       Date:  2012-07-17

5.  Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread.

Authors:  Chun-Ta Liao; Kang-Hsing Fan; Chien-Yu Lin; Hung-Ming Wang; Shiang-Fu Huang; I-How Chen; Chung-Jan Kang; Shu-Hang Ng; Chuen Hsueh; Li-Yu Lee; Chih-Hung Lin; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-21       Impact factor: 9.236

6.  A combined analysis of maximum standardized uptake value on FDG-PET, genetic markers, and clinicopathological risk factors in the prognostic stratification of patients with resected oral cavity squamous cell carcinoma.

Authors:  Chun-Ta Liao; Chia-Hsun Hsieh; Wen-Lang Fan; Shu-Hang Ng; Nai-Ming Cheng; Li-Yu Lee; Chuen Hsueh; Chien-Yu Lin; Kang-Hsing Fan; Hung-Ming Wang; Chih-Hung Lin; Chung-Kan Tsao; Chung-Jan Kang; Tuan-Jen Fang; Shiang-Fu Huang; Kai-Ping Chang; Li-Ang Lee; Ku-Hao Fang; Yu-Chien Wang; Lan-Yan Yang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-06       Impact factor: 9.236

7.  SUVmax for predicting regional control in oropharyngeal cancer.

Authors:  Lisa W Lekanne Dit Deprez; Grégoire B Morand; Christian Thüring; Shila Pazahr; Martin W Hüllner; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-15       Impact factor: 2.503

8.  Preoperative [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse.

Authors:  Chun-Ta Liao; Joseph Tung-Chieh Chang; Hung-Ming Wang; Shu-Hang Ng; Shiang-Fu Huang; I-How Chen; Chuen Hsueh; Li-Yu Lee; Chih-Hung Lin; Ann-Joy Cheng; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

9.  FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer.

Authors:  Giwon Kim; Yeon Sil Kim; Eun Ji Han; Ie Ryung Yoo; Jin-Ho Song; Sang-Nam Lee; Jong Hoon Lee; Byung-Oak Choi; Hong-Seok Jang; Sei-Chul Yoon
Journal:  Radiat Oncol J       Date:  2011-12-28

10.  Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma.

Authors:  Hsuan-Ho Chen; Hung-Ming Wang; Kang-Hsing Fan; Chien-Yu Lin; Tzu-Chen Yen; Chun-Ta Liao; I-How Chen; Chung-Jan Kang; Shiang-Fu Huang
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.